Standigm

Standigm is a workflow AI-driven drug discovery company, striving to revolutionize the pharmaceutical industry. Founded in 2015 and headquartered in South Korea, the company has made substantial advancements in the field. With a focus on biotechnology, health care, and pharmaceuticals, Standigm has developed proprietary AI platforms that cover target identification, lead generation, and the generation of commercially valuable drug pipelines.

One of the company's significant achievements includes the successful generation of First-in-Class lead compounds within seven months, showcasing the efficiency and effectiveness of its AI-powered drug discovery workflow. Standigm also pioneered the automation of molecular design workflow through DarkMolFactory™, contributing to the advancement of AI-driven industrializing drug discovery.

Recently, Standigm closed a remarkable $10.00M Series D investment led by Pavilion Capital on 30 June 2021, further validating its potential and success in the market. The company's AI platforms such as Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing, have positioned it as a frontrunner in driving innovation within the pharmaceutical landscape.

Overall, Standigm's progressive approach, technological prowess, and strategic investments make it a compelling player in the biotech and pharmaceutical sectors, with the potential to shape the future of drug discovery and development.